Patents Examined by Delbert K. Phillips
  • Patent number: 4868285
    Abstract: Imidazole/vancomycin complexes are prepared by containing an imidazole, preferably imidazole or N-methylimidazole, with a member of the vancomycin family, preferably Vancomycin itself.The complexes are useful in the purification of vancomycin.
    Type: Grant
    Filed: January 16, 1987
    Date of Patent: September 19, 1989
    Assignee: Glaxo Group Limited
    Inventor: Wilfred F. Wall
  • Patent number: 4783524
    Abstract: This invention relates to novel peptides having utility for promotion of growth and/or lactation in animals, to processes and DNA useful in production of such peptides, and to methods utilizing such peptides to promote growth or lactation in animals. In some embodiments, the invention is directed to peptides having bovine IGF-II biological activity, to production of such peptides, and to their use in effecting proliferation of certain cells (e.g. mammary epithelial or muscle) or in enhancing lactation in cattle or other animals.
    Type: Grant
    Filed: July 31, 1986
    Date of Patent: November 8, 1988
    Assignee: Monsanto Company
    Inventors: Brent R. Larsen, Ned R. Siegel, Claire E. Kotts, Michael F. McGrath, Sharon D. Ogden, Gwen G. Krivi, John C. Minnerly
  • Patent number: 4774226
    Abstract: A pharmaceutical preparation for the prophylactic treatment of allergies which contains as active ingredient an extract of pollen which contains nor more than 5% by weight, referred to the dry weight of the extract of pollen, of proteins having a high molecular weight or which is completely free of proteins of high molecular weight. The active ingredients of the inventive pharmaceutical preparation have themselves no allergen activity. To those human beings and children which in the years before suffered from severe symptoms of hay fever or asthma, the inventive pharmaceutical preparations were administered, preferably orally, during about three months before the allergy usually had occurred, for instance in the months February until April. By said administration the occurring of the pollen allergy in spring time and during the whole summer could be completely prevented.
    Type: Grant
    Filed: May 6, 1986
    Date of Patent: September 27, 1988
    Assignee: Cernitin S.A.
    Inventor: Ari Lewenstein
  • Patent number: 4749687
    Abstract: A series of novel peptide and polypeptide derivatives containing statine or derivatives thereof (e.g., aminostatine, cyclostatine) are disclosed that are useful for inhibiting the angiotensinogen-cleaving action of the enzyme renin. Of particular interest are compounds possessing the N-terminal sequence -Pro-Phe-His-Sta-Lys with the terminal proline nitrogen bonded to an amino-protecting acyl moiety or compounds possessing the N-terminal sequence -R-Phe-His-Sta-Lys- wherein R represents an amino protecting acyl group.
    Type: Grant
    Filed: March 10, 1986
    Date of Patent: June 7, 1988
    Assignee: Pfizer Inc.
    Inventors: Jasit S. Bindra, Edward F. Kleinman, Robert L. Rosati
  • Patent number: 4735933
    Abstract: The invention concerns novel renin-inhibitory peptides which are useful for treating renin associated hypertension and hyperaldosteronism. Processes for preparing the peptides, compositions containing them and methods of using them are included. Also included is a diagnostic test using the compounds to determine the presence of renin-associated hypertension or hyperaldosteronism.
    Type: Grant
    Filed: December 15, 1986
    Date of Patent: April 5, 1988
    Assignee: Warner-Lambert Company
    Inventors: James P. Hudspeth, James S. Kaltenbronn, Joseph T. Repine, W. Howard Roark, Michael A. Stier
  • Patent number: 4734420
    Abstract: Novel inhibitors of angiotensin converting enzyme having the general formula R - A - S - Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.
    Type: Grant
    Filed: May 2, 1980
    Date of Patent: March 29, 1988
    Assignee: University of Miami
    Inventors: James W. Ryan, Alfred Chung
  • Patent number: 4703033
    Abstract: Cyclosporins e.g. of formula II ##STR1## in which X is -MeBmt- or -dihydro-MeBmt- andY is -.alpha.Abu-, -Thr-, -Val- or -Nva-,wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, .alpha.-N-methylated .alpha.-amino acid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity. Intermediate cyclosporin poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of cyclosporins of formula II above wherein X and Y have the meanings given above and Z is -Sar-, in which the said residue Z is de-protonated, are also novel and part of the invention.
    Type: Grant
    Filed: March 7, 1986
    Date of Patent: October 27, 1987
    Assignee: Sandoz Ltd.
    Inventor: Dieter Seebach
  • Patent number: 4699898
    Abstract: A tripeptide and derivatives thereof are described that amplify mammalian immune response. A purification process, methods of using, and pharmaceutical compositions for using the product are disclosed.
    Type: Grant
    Filed: December 26, 1985
    Date of Patent: October 13, 1987
    Assignee: Imreg, Inc.
    Inventor: A. Arthur Gottlieb
  • Patent number: 4694070
    Abstract: Water soluble xanthylium derivative substrates of rhodamine 110 and rhodol permit spectrophotometric and fluorescent measurements of trypsin-like enzymes without the addition of organic solvent additives and/or special water solubilizing agents. These novel substrates exhibit increased sensitivity for determining low levels of activity of trypsin-like enzymes such as proteolytic enzymes, cofactors, activators, antiactivators, and inhibitors. These substrates can be substituted for fibrinogen or monitor the pathways of blood coagulation.
    Type: Grant
    Filed: May 28, 1985
    Date of Patent: September 15, 1987
    Assignee: Coulter Electronics, Inc.
    Inventors: Gary A. Mitchell, Gerald E. Jaffe, Marilyn M. Solorzano
  • Patent number: 4605512
    Abstract: Small peptides that display the specificity of FMD viral antigens. The peptides are useful in compositions and methods for the protection of animals for at least some time from FMD viral infections. The peptides of this invention may be prepared by conventional synthetic methods, recombinant DNA technology or a combination of the two. They may also be modified in composition and conformation to improve further their specific antigenic properties.
    Type: Grant
    Filed: March 25, 1983
    Date of Patent: August 12, 1986
    Assignee: Biogen N.V.
    Inventors: Heinz E. Schaller, Eberhard P. Pfaff
  • Patent number: 4431635
    Abstract: Disclosed herein are peptide analogs of the luteinizing hormone releasing hormone (LH-RH) which are potent antagonists of LHRH. The analogs differ in structure from LH-RH by having different amino acid residues at positions 1, 2 and 6, and optionally at positions 3 and 10. Methods for preparing and using these analogs are described.
    Type: Grant
    Filed: January 20, 1982
    Date of Patent: February 14, 1984
    Inventors: David H. Coy, Andrew V. Shally
  • Patent number: 4352788
    Abstract: Compounds for use in non-ionic X-ray contrasting materials having the formula ##STR1## in which (H0).sub.2-3 alkyl is 1,3-dihydroxyisopropyl, 2,3-dihydroxypropyl or 1,3-dihydroxy-2-hydroxymethylisopropyl,R is hydrogen or methyl, andR.sub.1 is an alkyl residue with 1 to 5 carbon atoms.These compounds possess high water-solubility as well as excellent stability against hydrolysis. Methods for preparation and use of the compounds are also disclosed.
    Type: Grant
    Filed: July 30, 1980
    Date of Patent: October 5, 1982
    Assignee: Bracco Industria Chimica S.p.A.
    Inventors: Ernst Felder, Davide Pitre
  • Patent number: 4328134
    Abstract: There are disclosed peptides of the formula A-B-C and pharmaceutically acceptable salts thereof, in which A is selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, and L-homo-pyroglutamyl; B is selected from the group consisting of L-histidyl, L-3'-methylhistidyl, D-histidyl, L-phenylalanyl, L-p-aminophenylalanyl, and L-.beta.-(pyrazolyl-1)alanyl; and C is selected from the group consisting of glycine and lower alkyl esters thereof, glycinamide and lower alkyl amides thereof, 2-amino-1-hydroxyethyl, D-alanine, L-.beta.-(2-thienyl)-alanine, and NHR.sup.1 in which R.sup.1 is lower alkyl, with the proviso that C may not be glycine or glycinamide when A is L-pyroglutamyl and B is L-histidyl.The compounds have anorexigenic properties, inhibit excessive gastric and pancreatic secretion, and cause activation in the CNS. Methods for their preparation and use are also disclosed.
    Type: Grant
    Filed: May 6, 1980
    Date of Patent: May 4, 1982
    Inventors: Andrew V. Schally, David H. Coy
  • Patent number: 4301065
    Abstract: The invention is concerned with novel polypeptides and processes for the synthesis thereof.It is concerned with compounds having the sequenceX-Gln-Gly-Gly-Yin which Y represents -Ser-Asn and X represents Ser-, Lys-Ser-, Ala-Lys-Ser-, Glx-Ala-Lys-Ser-; Glx representing Pyro-Glu or Gln; and when X represents Glx-Ala-Lys-Ser-, Y may in addition represent -Ser; as well as their derivatives comprising one or two modified amino acids, with the exception of the unmodified compound PyroGlu-Ala-Lys-Ser-Gln-Gly-Ser-Asn.These polypeptides are useful as medicines.
    Type: Grant
    Filed: May 24, 1978
    Date of Patent: November 17, 1981
    Assignee: Agence Nationale de Valorisation de la Recherche (ANVAR)
    Inventors: Jean-Francois Bach, Mireille Dardenne, Jean-Marie Pleau, Jean Hamburger, Evanghelos Bricas, Jean Martinez, Didier Blanot, Genevieve Auger
  • Patent number: 4299762
    Abstract: A-30912D nucleus, which is prepared by enzymatic deacylation of an antibiotic selected from A-30912 factor D and tetrahydro-A-30912D using an enzyme produced by the Actinoplanaceae, preferably by Actinoplanes utahensis. A-30912D nucleus and salts thereof are useful intermediates to prepare new semi-synthetic antifungal agents.
    Type: Grant
    Filed: August 25, 1980
    Date of Patent: November 10, 1981
    Assignee: Eli Lilly and Company
    Inventors: Bernard J. Abbott, David S. Fukuda
  • Patent number: RE30473
    Abstract: This invention is directed toward pharmacologically active compounds of the formula ##STR1## wherein A represents a nitrogen atom which may be substituted by a methyl, cyclopropylmethyl, di(C.sub.1-4 alkyl)aminoethyl, methoxymethyl or hydroxyethyl group and B represents a carbonyl group or A and B together represent a grouping of the formula ##STR2## in which R.sup.a represents a hydrogen or a lower alkyl or hydroxymethyl group and X represents a nitrogen atom or C-R.sup.b wherein R.sup.b represents a hydrogen atom or a lower alkyl or hydroxymethyl group; R represents a halogen atom or a nitro or trifluoromethyl group; R.sup.1 represents a hydrogen atom or a lower alkyl group; R.sup.2 represents an acyl group derived from a naturally occurring amino acid (all such groups which contain an asymmetric carbon atom having the L- or D,L-configuration) and R.sup.3 represents a phenyl, halophenyl or 2-pyridyl group and acid addition salts thereof.
    Type: Grant
    Filed: July 31, 1978
    Date of Patent: January 6, 1981
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Cedric H. Hassall, William H. Johnson, Antonin Krohn, Carey E. Smithen, William A. Thomas